However, IFNs have been replaced or relegated to a second-line therapy due to drug resistance, as it overpowers the curative effect of IFN-α in HCC or induces severe liver decompensation when administered to patients with cirrhosis [5]. Here, IFNA1 is linked to hepatocellular carcinoma.